There are a number of Phase 1 (and some 2a) trials in the pipeline specifically for the implementation of allogenic NK cellular transfer, CAR-NK cells secreting an IL15 superagonist, and anakinra or rhIFNy adjunctives in COVID-19 and sepsis with hyperinflammation. Here, IL15 is linked to Sepsis.